DÜSSELDORF, Germany--(BUSINESS WIRE)--LenioBio GmbH, a TechBio company commercializing its ALiCE® cell-free protein expression platform, today announced a collaborative agreement with Twist Bioscience Corporation. The collaboration will integrate our ALiCE® platform with Twist's DNA manufacturing and automation capabilities to accelerate the design–build–test cycle for protein expression services—delivering experimental results back to customers' and partners' AI models faster. “AI can design n.

Twist Bioscience (TWST) delivered strong Q2 results, driven by AI-enabled drug discovery. NGS growth was soft due to a demand air pocket caused by a large customer. Growth is expected to rebound as this company's commercial test volumes ramp. Twist's fundamentals are likely to continue improving in coming quarters. Growth investments will create modest near-term margin headwinds though.

Twist Bioscience Corporation (NASDAQ:TWST) on Monday reported a loss for its fiscal 2026 second quarter.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value biotech company, today announced that a total of 115,279 equity awards, consisting of 101,931 restricted stock units (“RSUs”) and up to 13,348 performance stock units (“PSUs”), will be granted to 53 recently hired individuals, in each case as an inducement material to their acceptance of employment w.

Twist Bioscience Corporation (TWST) Q2 2026 Earnings Call Transcript

Twist Bioscience Corporation (NASDAQ:TWST) shares are down on Monday as the company reported its fiscal 2026 second-quarter financial results.

Twist Bioscience (TWST) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $0.66 per share a year ago.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today expanded its clonal genes portfolio with the early access launch of Complex Genes. “As research in nucleic acid therapeutics and AI-guided protein design and therapeutics discovery accelerate, scientists need a reliable partner to consistently deliver genes rapidly at scale and with more complex sequences,” said Emily M. Leproust, Ph.D., CEO and co-founder.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the second quarter fiscal 2026 ended March 31, 2026. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal second quarter 2026 earnings report and the investor presentation, or click https://investors.tw.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it will issue its financial results for the fiscal 2026 second quarter ended March 31, 2026, before the opening of the market on May 4, 2026. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business.